JS 112
Alternative Names: JS-112; WJ-05129Latest Information Update: 12 Apr 2023
Price :
$50 *
At a glance
- Originator Wigen Biomedicine
- Developer Shanghai Junshi Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Aurora kinase A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 30 Mar 2023 Phase-I clinical trials in Solid tumours in China (PO) (Shanghai Junshi Biosciences pipeline, April 2023)
- 29 Apr 2022 Suzhou Junjing BioSciences plans a phase I/II trial in Solid tumours (Metastatic, Late stage disease disease, In adults, In the elderly) in China (NCT05326035)
- 01 Feb 2022 NMPA approves IND application for JS 112 in Solid tumours in China